MSI-H/dMMR + PD-L1 expression
|
Neuroendocrine Tumor
|
MSI-H/dMMR + PD-L1 expression
|
Neuroendocrine Tumor
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
MSI-H/dMMR + PD-L1 expression
|
Triple Negative Breast Cancer
|
MSI-H/dMMR + PD-L1 expression
|
Triple Negative Breast Cancer
|
atezolizumab Resistant: C4 – Case Studies
|
atezolizumab Resistant: C4 – Case Studies
|
MSI-H/dMMR + PD-L1 expression
|
Triple Negative Breast Cancer
|
MSI-H/dMMR + PD-L1 expression
|
Triple Negative Breast Cancer
|
sacituzumab govitecan-hziy Resistant: C4 – Case Studies
|
sacituzumab govitecan-hziy Resistant: C4 – Case Studies
|
MSI-H/dMMR + PD-L1 expression
|
Cholangiocarcinoma
|
MSI-H/dMMR + PD-L1 expression
|
Cholangiocarcinoma
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|